menu search

Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...

May 31, 2023, 3:00 am

Annexon (annx) stock down more than 50% last week: here's why

Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geog...

May 30, 2023, 11:55 am

Wall street bulls look optimistic about enphase energy (enph): should you buy?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports ab...

May 30, 2023, 10:40 am

Genprex wins approval to advance phase 2 expansion of acclaim-1 trial of reqorsa combined with tagrisso in advanced non-small cell lung cancer

Genprex Inc. revealed that it has completed the phase 1 portion of the Acclaim-1 ...

May 30, 2023, 9:32 am

Revive therapeutics staying the course on phase 3 trial of bucillamine in covid-19 patients after meeting with fda

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has issued an update on the phase 3 trial of its drug Bu...

May 30, 2023, 9:01 am

Numinus wellness announces largest-of-its-kind study of psilocybin therapy to treat depression

Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said its wholly-owned subsidiary Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin ther...

May 30, 2023, 8:33 am

Glycomimetics: insider buying continues, and chart looks healthy

GlycoMimetics' phase 3 study of uproleselan for acute myeloid leukemia is expected to continue until ea...

May 30, 2023, 8:02 am

Eur/usd technical: bears may be getting exhausted

EUR/USD Technical: Bears May Be Getting Exhausted The current minor downtrend phase for EUR/USD from it...

May 30, 2023, 7:57 am

Spain may preliminary cpi +3.2% vs +3.5% y/y expected

Prior +4.1%HICP +2.9% vs +3.4% y/y expectedPrior +3.8%The headline reading and the EU-harmonised reading will be a welcome development for the ECB. An...

May 30, 2023, 7:00 am

Immunic to participate in scientific and investor conferences in june

NEW YORK , May 30, 2023 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,...

May 30, 2023, 6:30 am

Eur/usd technical: bears may be getting exhausted

The current minor downtrend phase for EUR/USD from its 3 May 2023 high of 1.1092 is showing signs of ex...

May 30, 2023, 5:43 am

Logitech: normalization in inventory level to continue, thereby improving gross margin

Logitech's 1H24 guidance reflects a challenging macroeconomic environment and decreased IT spending, but I expect LOGI to gain market share during the...

May 30, 2023, 4:12 am

Nasdaq 100 meltup makes fdn a near-term winner (technical analysis)

The Nasdaq 100 and Invesco QQQ Trust ETF are experiencing a rapid surge, potentially leading to a "meltup" pha...

May 30, 2023, 3:26 am

Arrow exploration sees high rates in first production test at carrizales norte

Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) has seen what it calls “an extremely important” result from the Carrizales Norte-1 (CN-1) w...

May 30, 2023, 2:57 am

Madrigal: setting the pace in the nash market (rating upgrade)

Madrigal Pharmaceuticals' drug, resmetirom, for non-alcoholic fatty liver diseases, received FDA's Breakthrough Therapy designation. The company is no...

May 30, 2023, 1:19 am

Pfizer: the new oral weight loss therapy could be a game changer

Pfizer has declined over 36% in the past two years, as investors worry about the company's growth post-COVID. The company's new oral weight loss thera...

May 30, 2023, 12:11 am

Eurusd daily analysis – may 29, 2023

The EURUSD currency pair has been struggling to break free from the grip of a persistent downtrend, as indicated by its position below a descending tr...

May 29, 2023, 10:43 am

Ultragenyx: a promising bet on rare genetic disorder therapies

Ultragenyx's pipeline boasts a diverse array of gene therapy candidates, including UX111, DTX401, DTX301, and UX701, offering transformative potential...

May 29, 2023, 7:15 am

Travere: turbulent journey with filspari, downgrading to sell

FILSPARI's inability to significantly change FSGS disease trajectory (eGFR) in the phase 3 DUPLEX study...

May 29, 2023, 3:49 am

Achieve: exciting smoking cessation drug approval could come soon

Efficacy: phase 3 ORCA-3 trial showed significant efficacy of cytisinicline in smoking cessation, reinf...

May 28, 2023, 4:39 am


Search within

Pages Search Results: